YBYongyan Bi

Yongyan Bi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yongyan Bi has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Cong Luo

    Department of Neurosurgery Minhang Hospital, Fudan University Shanghai China

    1 shared publication
  • Fulin Xu

    Department of Neurosurgery Minhang Hospital, Fudan University Shanghai China

    1 shared publication
  • Jie Ji

    Department of Rehabilitation Medicine Minhang Hospital, Fudan University Shanghai China

    1 shared publication
  • Mingliang Chen

    Research and Translational Laboratory of Acute Injury and Secondary Infection, Department of Laboratory Medicine Minhang Hospital, Fudan University Shanghai China

    1 shared publication
  • Xiaoliu Li

    Department of Rehabilitation Medicine Minhang Hospital, Fudan University Shanghai China

    1 shared publication
  • Ye Jiang

    Department of Neurosurgery Minhang Hospital, Fudan University Shanghai China

    1 shared publication

Latest Publications

  • Microbial‐Engineered Fluorescent Nanocarrier for Ion Ratiometric Sensing and sTREM‐1‐Mediated EBV Inhibition

    by Mingliang Chen, Jie Ji, Xiaoliu Li, Cong Luo, Ye Jiang, Fulin Xu, Yongyan Bi

    Epstein–Barr virus (EBV), a widespread human γ‐herpesvirus, is associated with infectious mononucleosis and several malignancies, posing a major public health challenge. Acyclovir (ACV), the first‐line antiviral drug, is limited by poor solubility, short half‐life, and low bioavailability. To overcome these drawbacks, we designed a hyaluronic acid–based nanocarrier modified with microbial extracts and a fluorescent small molecule (1‐HA‐2), and constructed an ACV‐loaded nanosystem (1‐HA‐2@ACV) with improved drug loading, fluorescence responsiveness, and aqueous stability, enabling both therapeutic delivery and ion sensing. Notably, 1‐HA‐2@ACV allows sensitive detection of Na + and PO 4 3− , two clinically relevant ions whose dysregulation is closely linked to EBV‐associated disease progression, drug safety, and therapeutic monitoring. In EBV‐susceptible cells, EBV infection markedly increased EBNA1 and sTREM‐1 expression, whereas treatment with 1‐HA‐2@ACV significantly inhibited viral replication and reduced sTREM‐1 overexpression more effectively than free ACV, while blank nanoparticles showed no effect. These findings suggest that 1‐HA‐2@ACV not only enhances the therapeutic efficacy of ACV but also provides a dual‐function platform for EBV‐targeted therapy and real‐time monitoring through modulation of sTREM‐1 pathways and ion‐associated biomarkers.